

UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK

-----X  
ASSOCIATION FOR MOLECULAR PATHOLOGY;  
AMERICAN COLLEGE OF MEDICAL GENETICS;  
AMERICAN SOCIETY FOR CLINICAL PATHOLOGY;  
COLLEGE OF AMERICAN PATHOLOGISTS;  
HAIG KAZAZIAN, MD; ARUPA GANGULY, PhD;  
WENDY CHUNG, MD, PhD; HARRY OSTRER, MD;  
DAVID LEDBETTER, PhD; STEPHEN WARREN, PhD;  
ELLEN MATLOFF, M.S.; ELSA REICH, M.S.;  
BREAST CANCER ACTION; BOSTON WOMEN'S  
HEALTH BOOK COLLECTIVE; LISBETH CERIANI;  
RUNI LIMARY; GENAE GIRARD; PATRICE FORTUNE;  
VICKY THOMASON; KATHLEEN RAKER,

Plaintiffs,

09 Civ. 4515 (RWS)

v.

ECF Case

UNITED STATES PATENT AND TRADEMARK  
OFFICE; MYRIAD GENETICS; LORRIS BETZ,  
ROGER BOYER, JACK BRITAIN, ARNOLD B.  
COMBE, RAYMOND GESTELAND, JAMES U.  
JENSEN, JOHN KENDALL MORRIS, THOMAS PARKS,  
DAVID W. PERSHING, and MICHAEL K. YOUNG,  
in their official capacity as Directors of the University  
of Utah Research Foundation,

DECLARATION OF  
Mark Sobel

Defendants.

-----X

I, Mark Sobel, declare under penalty of perjury:

1. I am the Executive Officer of the Association for Molecular Pathology (AMP),  
one of the plaintiffs in this case.

2. AMP is a not-for-profit scientific society dedicated to the advancement,  
practice, and science of clinical molecular laboratory medicine and translational research  
based on the applications of genomics and proteomics. AMP members participate in  
basic and translational research aimed at broadening the understanding of gene/protein


structure and function, disease processes, and molecular diagnostics, and provide clinical medical services for patients, including diagnosis of breast cancer.

3. AMP has brought this case on behalf of its members some of whom are ready, willing, and able to engage in research and clinical practice involving the *BRCA1* and *BRCA2* genes if the patents are invalidated. One or more AMP members are submitting separate declarations concerning their ability to engage in research and clinical practice now prohibited by the patents.

4. This case seeks to invalidate broad gene patents such as those listed in the Complaint. That interest is germane to the purposes of AMP. One of AMP's purposes is to enable its members to advance human understanding of genes. The patent impedes that purpose. Another purpose of AMP is to ensure that the patients for whom our members are responsible receive high quality, accurate tests when necessary. The patent impedes that purpose.

5. Over the years, AMP has issued or signed statements concerning gene patents as a regular part of its mission. See e.g. [http://www.amp.org/Gov/AMPSACGHS\\_GenePatents\\_Final\\_051509.pdf](http://www.amp.org/Gov/AMPSACGHS_GenePatents_Final_051509.pdf) (visited July 30, 2009).

I declare, pursuant to 28 U.S.C. § 1746, under penalty of perjury under the laws of the United States, that the foregoing is true and correct to the best of my knowledge and belief.

  
\_\_\_\_\_  
Mark Sobel

Executed on August 14, 2009